HCM
AYTU icon

Highbridge Capital Management’s AYTU BioPharma AYTU Stock Holding History

Highbridge Capital Management’s Portfolio AYTU Stock Details AYTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-267
Closed -$681K – 916
2018
Q1 		$681K Buy
+267
New +$1.84M 0.01% 603

Other funds holding AYTU

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KJHP
K.J. Harrison & Partners Toronto, Ontario, Canada $608M AUM 45.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
CCM
Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Highbridge Capital Management's AYTU Position: Q2 2018 in Review

Highbridge Capital Management sold out of AYTU BioPharma (AYTU) in Q2 2018, closing a stake of 267 shares — an estimated $681K sold.

Highbridge Capital Management first reported a position in AYTU in Q1 2018 and held it in 1 quarter. The position peaked at $681K in Q1 2018. 14 funds tracked by Wall St. Rank hold AYTU as of Q2 2018.

  • Highbridge Capital Management reported no remaining AYTU BioPharma position as of Q2 2018 after selling out during the quarter.
  • Highbridge Capital Management sold 267 AYTU BioPharma shares in Q2 2018, an estimated $681K.
  • Highbridge Capital Management first reported a position in AYTU BioPharma in Q1 2018 and held it in 1 quarter.
  • Highbridge Capital Management's AYTU BioPharma position peaked at $681K in Q1 2018.
  • 14 funds tracked by Wall St. Rank held AYTU BioPharma as of Q2 2018.

Based on Highbridge Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.